RBC Affirms PTC Therapeutics (PTCT) at 'Sector Perform'; Doesn't See Translarna Appeal with Solid Chance
- Wall Street ends higher, investors juggle Fed nerves with AI enthusiasm
- Apple in talks with Google to use generative AI in iPhones- Bloomberg
- World shares cheer China data, as central banks line up
- Oil prices climb 2% to 4-month high on lower Iraq, Saudi exports
- Meta Platforms is a new Top Pick at Mizuho, analyst sees upside to consensus
- After-hours movers: ANSYS, National CineMedia, and more
- Midday movers: Google, Pepsi rise; Boeing, Zillow fall
- Midday movers: Adobe, Zillow fall; Micron rises
- After-hours movers: Adobe Systems slumps; Rivian, Ulta Beauty gain
- Midday movers: Tesla, Nvidia fall premarket; Robinhood, Dollar General rise
Sarepta Therapeutics (SRPT) Sees Intra-Day Selling Pressure
October 19, 2016 10:30 AM EDTSarepta Therapeutics (NASDAQ: SRPT) seeing notable intra-day pressure. Shares down 3.2%.
... MoreSarepta Therapeutics (SRPT) Shares Continue to Session Lows
October 19, 2016 10:30 AM EDTSarepta Therapeutics (NASDAQ: SRPT) shares are trading to session lows. The stock is down 3.6 percent with elevated volume.
... MoreCredit Suisse Starts Sarepta Therapeutic (SRPT) at Outperform
October 18, 2016 6:34 AM EDTCredit Suisse initiates coverage on Sarepta Therapeutic (NASDAQ: SRPT) with a Outperform rating and a price target of $68.00.
Analyst Alethia Young commented, "Sarepta is an RNA-based therapeutics company currently focused on drug development in Duchenne Muscular Dystrophy (DMD). Sarepta received accelerated... More
PTC Therapeutics (PTCT) Says FDA Denied First Appeal of the Refuse to File Letter
October 17, 2016 8:02 AM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) today provided a regulatory update on Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
U.S. regulatory update
PTC Therapeutics announced today that at the end of last week, the Office of Drug Evaluation I (ODE-I) of the U.S. Food and Drug Administration (FDA) denied the company's first appeal of the refuse to file letter issued by the FDA's Division of Neurological Products (DNP) on February 22, 2016 regarding PTC's New Drug Application (NDA) for Translarna for the treatment of nonsense mutation Duchenne muscular... More